LIANBIO-ADR (LIAN) Fundamental Analysis & Valuation

NASDAQ:LIAN • US53000N1081

Current stock price

0.319 USD
-0.03 (-8.28%)
At close:
0.32 USD
+0 (+0.31%)
After Hours:

This LIAN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LIAN Profitability Analysis

1.1 Basic Checks

  • In the past year LIAN has reported negative net income.
  • In the past year LIAN has reported a negative cash flow from operations.
LIAN Yearly Net Income VS EBIT VS OCF VS FCFLIAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • LIAN has a better Return On Assets (-33.47%) than 68.54% of its industry peers.
  • Looking at the Return On Equity, with a value of -43.49%, LIAN is in the better half of the industry, outperforming 71.77% of the companies in the same industry.
Industry RankSector Rank
ROA -33.47%
ROE -43.49%
ROIC N/A
ROA(3y)-43.5%
ROA(5y)N/A
ROE(3y)-54.1%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LIAN Yearly ROA, ROE, ROICLIAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -20 -40 -60

1.3 Margins

  • LIAN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIAN Yearly Profit, Operating, Gross MarginsLIAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. LIAN Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, LIAN has less shares outstanding
  • LIAN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LIAN Yearly Shares OutstandingLIAN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 20M 40M 60M 80M 100M
LIAN Yearly Total Debt VS Total AssetsLIAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

  • LIAN has an Altman-Z score of -2.81. This is a bad value and indicates that LIAN is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of LIAN (-2.81) is comparable to the rest of the industry.
  • LIAN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.81
ROIC/WACCN/A
WACCN/A
LIAN Yearly LT Debt VS Equity VS FCFLIAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 10.07 indicates that LIAN has no problem at all paying its short term obligations.
  • LIAN has a Current ratio of 10.07. This is in the better half of the industry: LIAN outperforms 78.40% of its industry peers.
  • LIAN has a Quick Ratio of 10.07. This indicates that LIAN is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of LIAN (10.07) is better than 78.40% of its industry peers.
Industry RankSector Rank
Current Ratio 10.07
Quick Ratio 10.07
LIAN Yearly Current Assets VS Current LiabilitesLIAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. LIAN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.32% over the past year.
EPS 1Y (TTM)28.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, LIAN will show a very strong growth in Earnings Per Share. The EPS will grow by 27.35% on average per year.
  • The Revenue is expected to grow by 171.95% on average over the next years. This is a very strong growth
EPS Next Y16%
EPS Next 2Y7%
EPS Next 3Y16.47%
EPS Next 5Y27.35%
Revenue Next Year-100%
Revenue Next 2Y123.61%
Revenue Next 3Y-25.99%
Revenue Next 5Y171.95%

3.3 Evolution

LIAN Yearly Revenue VS EstimatesLIAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2027 2028 2029 2030 500M 1B 1.5B
LIAN Yearly EPS VS EstimatesLIAN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. LIAN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LIAN. In the last year negative earnings were reported.
  • Also next year LIAN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIAN Price Earnings VS Forward Price EarningsLIAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIAN Per share dataLIAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LIAN's earnings are expected to grow with 16.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7%
EPS Next 3Y16.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LIAN Dividend Analysis

5.1 Amount

  • No dividends for LIAN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LIAN Fundamentals: All Metrics, Ratios and Statistics

LIANBIO-ADR

NASDAQ:LIAN (3/18/2024, 8:21:48 PM)

After market: 0.32 +0 (+0.31%)

0.319

-0.03 (-8.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25
Earnings (Next)05-09
Inst Owners0.15%
Inst Owner Change-0.71%
Ins Owners2.64%
Ins Owner Change0%
Market Cap34.47M
Revenue(TTM)N/A
Net Income(TTM)-87.99M
Analysts43.33
Price Target3.98 (1147.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.92%
Min EPS beat(2)31.2%
Max EPS beat(2)34.64%
EPS beat(4)4
Avg EPS beat(4)31.38%
Min EPS beat(4)20.85%
Max EPS beat(4)38.84%
EPS beat(8)7
Avg EPS beat(8)26.56%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)28.46%
EPS NY rev (1m)21.86%
EPS NY rev (3m)21.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0
BVpS1.87
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.47%
ROE -43.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.5%
ROA(5y)N/A
ROE(3y)-54.1%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.07
Quick Ratio 10.07
Altman-Z -2.81
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)491.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y16%
EPS Next 2Y7%
EPS Next 3Y16.47%
EPS Next 5Y27.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y123.61%
Revenue Next 3Y-25.99%
Revenue Next 5Y171.95%
EBIT growth 1Y9.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year291.15%
EBIT Next 3Y-8.48%
EBIT Next 5Y34.68%
FCF growth 1Y54.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.22%
OCF growth 3YN/A
OCF growth 5YN/A

LIANBIO-ADR / LIAN Fundamental Analysis FAQ

What is the fundamental rating for LIAN stock?

ChartMill assigns a fundamental rating of 3 / 10 to LIAN.


What is the valuation status for LIAN stock?

ChartMill assigns a valuation rating of 0 / 10 to LIANBIO-ADR (LIAN). This can be considered as Overvalued.


Can you provide the profitability details for LIANBIO-ADR?

LIANBIO-ADR (LIAN) has a profitability rating of 1 / 10.


What is the earnings growth outlook for LIANBIO-ADR?

The Earnings per Share (EPS) of LIANBIO-ADR (LIAN) is expected to grow by 16% in the next year.